Jason Coloma, Maze Therapeutics CEO
Sanofi's next chapter in Pompe: $150M for Maze pact as the biotech gears up in CKD
With nearly $400 million to its name since Third Rock launched the biotech in 2019, Maze Therapeutics has lined up a deal that sees Sanofi …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
